Semax

What is Semax?

Semax is a synthetic heptapeptide derived from the 4-10 fragment of adrenocorticotropic hormone (ACTH). Developed at the Institute of Molecular Genetics in Moscow, it consists of the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro, where the Pro-Gly-Pro C-terminal extension (identical to Selank's extension) provides enzymatic stability. Semax was approved in Russia in 2011 as a nasal spray for treatment of cognitive disorders, stroke recovery, and optic nerve diseases.

Despite being derived from ACTH, Semax does not stimulate the adrenal cortex or affect cortisol production. The biological activity of the ACTH(4-10) fragment is entirely separate from ACTH's hormonal functions. Instead, Semax acts as a potent neurotrophic agent, increasing the expression of BDNF and its receptor TrkB in the hippocampus and prefrontal cortex [2]. It also modulates the expression of genes involved in neuronal survival, synaptic plasticity, and neurotransmitter metabolism.

Clinical studies in Russia have documented Semax's efficacy in ischemic stroke recovery, where it improved neurological outcomes when administered within 6 hours of onset [1]. The compound has also shown benefits in optic nerve atrophy, ADHD in children, and cognitive decline associated with chronic cerebrovascular insufficiency. Mechanistically, Semax activates the MAPK/ERK pathway, increases NGF and BDNF expression, provides antioxidant neuroprotection, and modulates dopaminergic and serotonergic neurotransmission.

Mechanism of Action

Semax's nootropic and neuroprotective effects are mediated through multiple converging pathways, all centered on neuronal health and plasticity:

BDNF & NGF Upregulation

The primary mechanism of Semax involves potent upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression, particularly in the hippocampus and basal forebrain. BDNF promotes synaptic plasticity, long-term potentiation, and neuronal survival. In rat hippocampal studies, Semax increased BDNF mRNA expression by 1.4–2.8 fold within hours of administration [2]. This neurotrophin-boosting effect is considered the central mechanism underlying Semax's cognitive enhancement properties.

MAPK/ERK Signaling Pathway

Semax activates the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling cascade. This pathway is essential for synaptic plasticity, memory consolidation, and neuronal differentiation. ERK activation by Semax promotes transcription of genes involved in long-term memory formation and provides neuroprotective effects against ischemic and oxidative damage [3].

Dopaminergic & Serotonergic Modulation

Semax modulates both dopaminergic and serotonergic neurotransmission without acting as a direct receptor agonist. Research demonstrates that it influences dopamine turnover in the striatum and cortex and modulates serotonin metabolism. These effects likely contribute to the attention-enhancing and mood-modulating properties observed in clinical use. The dopaminergic modulation also explains the rare reports of anxiety at high doses.

Antioxidant & Anti-Inflammatory Neuroprotection

In ischemic stroke models, Semax has demonstrated significant neuroprotective effects through multiple pathways: reduction of lipid peroxidation, enhancement of antioxidant enzyme activity, suppression of pro-inflammatory cytokine expression (IL-1β, TNF-α), and inhibition of microglial activation [4]. These effects reduce secondary neuronal damage following acute brain injury.

Dosing Protocol

Semax is most commonly administered intranasally, though subcutaneous injection is an alternative route. It is a stimulating nootropic and should be used during waking hours.

Reconstitution Guide

Reconstitute lyophilized Semax with bacteriostatic water. The Pro-Gly-Pro extension provides reasonable stability. For intranasal use, transfer the reconstituted solution to a nasal spray device.

1. Remove the plastic cap from the Semax vial and wipe the rubber stopper with an alcohol swab. Allow to dry.
2. Draw 2.5 mL of bacteriostatic water into a sterile syringe. For a 5 mg vial, this yields a concentration of 2,000 mcg/mL.
3. Insert the needle through the rubber stopper at a slight angle. Inject the water slowly against the inner wall of the vial — do not spray directly onto the peptide powder.
4. Allow the vial to sit for 1–2 minutes. Gently roll the vial between your palms if needed. Do not shake or vortex.
5. The solution should be completely clear and colorless. Discard if you observe any cloudiness, particulate matter, or discoloration.

Injection Technique

Semax can be administered subcutaneously (SubQ) or intranasally. For SubQ injection, follow standard peptide injection technique.

1. Clean the injection site with an alcohol swab and allow it to air dry completely (approximately 30 seconds). Common sites: lower abdomen (2 inches from the navel), upper thigh, or upper outer arm.
2. Draw the dose. Insert the needle into the vial through the rubber stopper. Invert the vial and draw the calculated number of units slowly. Tap the syringe to move any air bubbles to the top, then push them out gently.
3. Pinch the skin at the injection site to create a fold of subcutaneous tissue. Insert the needle at a 45-degree angle in a quick, smooth motion. Release the skin fold.
4. Inject slowly. Depress the plunger steadily over 5–10 seconds. Withdraw the needle at the same angle it was inserted. Apply gentle pressure with a clean swab if needed.

Storage & Stability

Semax benefits from its Pro-Gly-Pro extension, which provides reasonable enzymatic stability. Proper storage practices are essential.

Side Effects & Considerations

Semax has been well-tolerated in Russian clinical practice across multiple approved indications, with a safety profile that supports its classification as a non-hormonal nootropic.

Commonly Reported

• Mild nasal irritation — with intranasal administration; transient stinging or dryness. Usually resolves within minutes.
• Headache — reported rarely, more common at higher doses (600+ mcg/dose).
• Mild stimulation or restlessness — particularly if administered too late in the day.

Theoretical Considerations

• Does NOT affect cortisol levels despite its ACTH origin — the (4-10) fragment lacks adrenocortical activity entirely.
• May increase anxiety in some individuals at high doses due to dopamine modulation effects. Start with lower doses to assess tolerance.
• Avoid evening dosing as the stimulating nootropic properties may interfere with sleep onset.
• No dependency, tolerance, or withdrawal effects reported in any published clinical study.
• Clinical data is predominantly from Russian researchers; independent Western replication is growing but limited.

Stacking Protocols

Semax is frequently studied alongside Selank, its anxiolytic counterpart. The two peptides share structural features but act through different mechanisms.

Semax + Selank (Complete Nootropic Stack)

The most well-documented nootropic peptide combination. Semax provides cognitive enhancement and neuroprotection (BDNF/NGF upregulation, MAPK activation) while Selank provides anxiolysis and mood stabilization (GABA modulation, enkephalin stabilization). The two peptides complement each other without pharmacological conflict.

Lifestyle Factors

Research suggests the following practices may enhance Semax's cognitive effects:

• Cognitive demand: Semax's neuroplasticity effects are use-dependent. Pair with challenging mental work, study sessions, or learning activities to maximize benefit during the enhanced plasticity window.
• Exercise: Physical activity independently increases BDNF. Combined with Semax, this may produce additive neurotrophic effects.
• Sleep: Memory consolidation occurs during sleep. Adequate rest (7–9 hours) maximizes the cognitive benefits of daytime Semax use.
• Omega-3 intake: DHA supports neuronal membrane fluidity and BDNF signaling, potentially complementing Semax's neurotrophin-boosting effects.

Related Peptides

Researchers studying Semax often investigate these related compounds:

Literature & Citations

1. Gusev EI, Skvortsova VI, Izhboldina GI, et al. The efficacy of semax in the treatment of patients with acute hemispheric ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PubMed
2. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PubMed
3. Agapova TY, Agniullin YV, Silachev DN, et al. Effect of semax on the temporary dynamics of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the rat hippocampus after global cerebral ischemia. Mol Biol. 2008;42(1):30-38. PubMed
4. Levitskaya NG, Sebentsova EA, Andreeva LA, et al. The neuroprotective effects of Semax in conditions of acute and chronic neurodegeneration models. Dokl Biol Sci. 2004;399:462-464. PubMed
5. Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. PubMed
6. Dmitrieva VG, Povarova OV, Skvortsova VI, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(5):651-657. PubMed
7. Gavrilova SA, Golubeva AV, Lipina TV, et al. Effect of Semax on the expression of genes encoding antioxidant enzymes in the rat brain under conditions of incomplete global ischemia. Dokl Biol Sci. 2006;410:391-393. PubMed